Misoprostol for cervical priming prior to hysteroscopy in postmenopausal and premenopausal nulliparous women: A multicentre randomised placebo controlled trial

Tasma, Maaike; Louwerse, Marjoleine; Hehenkamp, Wouter J.K.; Geomini, Peggy M. A. J.; Bongers, Marlies Y.; Veersema, Sebastiaan; Kesteren, Paul van; Tromp, Ellen; Huirne, Judith A.F.; Graziosi, Peppino G.C.M.

doi:10.1016/j.maturitas.2017.03.293

Cited by 7 publications

(32 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, non-pharmacological effects on pain can be studied in detail, such as the presence of a nurse guiding the patient, or the use of music or images. Work has already commenced on this by the authors' study group, comparing two types of gels used during gel infusion sonography, and a comparative study was performed using misoprostol vs placebo before hysteroscopy to determine the effect on pain [25]. For years, efforts have been made, in vain, to discover the best method for pain reduction in outpatient procedures, especially during hysteroscopy.…”

Section: Interpretation Of the Results Clinical Implications And Future Perspectivesmentioning

confidence: 99%

Electronic Continuous Pain Measurement vs Verbal Rating Scale in gynaecology: A prospective cohort study

Louwerse¹,

Hehenkamp²,

Kesteren

et al. 2021

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

To compare pain measured with a new electronic devicethe Continuous Pain Score Meter (CPSM)and the Verbal Rating Scale (VRS) during gynaecological procedures in an outpatient setting, and to correlate these outcomes with baseline anxiety and patient (in)tolerance to the procedure. Study design: This prospective cohort study was undertaken in two centres: a university hospital and a large teaching hospital in The Netherlands. Patients undergoing an outpatient hysteroscopy, colposcopy or ovum pick-up procedure for in-vitro fertilization in one of the two participating hospitals with availability of the CPSM were included. Pain was measured by both the CPSM and the VRS. Patient tolerance to the procedure was reported. Various outcomes of the CPSM were compared with those of the VRS and related to baseline anxiety scores.Results: Ninety-one of 108 included patients (84 %) used the CPSM correctly during the procedure, and it was possible to analyse the CPSM scores for 87 women (81 %). The CPSM scores were all linearly related to the VRS. The peak pain score on the CPSM (CPSM-PPS) had the strongest correlation with the VRS score for all three procedures. Higher CPSM-PPS was related to patient (in)tolerance to the procedure (p = 0.03-0.002). Anxiety at baseline was not correlated with pain perception, except for VRS during colposcopy (r = 0.39, p = 0.016). Conclusion:The majority of patients were able to use the CPSM correctly, resulting in detailed information on pain perception for each individual pain stimulus during three outpatient gynaecological procedures. The CPSM-PPS had the strongest correlation with the VRS score and patient (in)tolerance to the procedure.

show abstract

Section: Interpretation Of the Results Clinical Implications And Future Perspectivesmentioning

confidence: 99%

Electronic Continuous Pain Measurement vs Verbal Rating Scale in gynaecology: A prospective cohort study

Louwerse¹,

Hehenkamp²,

Kesteren

et al. 2021

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

show abstract

“…Misoprostol proved to reduce pain in nulliparous premenopausal women undergoing a hysteroscopy. As Mr Kesrouani correctly points out, adverse effects occurred significantly more often in this group compared with placebo: more nausea (17% [misoprostol] versus 11% [placebo]) as well as abdominal pain (24% [misoprostol] versus 15% [placebo]) . His dose‐finding study was able to demonstrate a relation between dosage and adverse effects: higher rates of nausea (11% [400 micrograms] versus 6% [200 micrograms]) and abdominal pain (25% [400 micrograms] versus 13% [200 micrograms]) …”

mentioning

confidence: 93%

“…We would like to take the opportunity to thank Mr Kesrouani for his positive response to our paper, published in the January issue of BJOG . We referred to his thorough, dose‐finding randomised trial in our discussion, regarding the possibility of using a lower dose of misoprostol …”

mentioning

confidence: 99%

See 1 more Smart Citation

Authors' reply re: Misoprostol for cervical priming prior to hysteroscopy in postmenopausal and premenopausal nulliparous women; a multi‐centre randomised placebo controlled trial

Tasma

2018

BJOG

View full text Add to dashboard Cite

“…The paper by Tasma et al . examined the reduction of pain by misoprostol compared with placebo prior to hysteroscopy and evaluated the difference in premenopausal and postmenopausal patients.…”

mentioning

confidence: 99%

Re: Misoprostol for cervical priming prior to hysteroscopy in postmenopausal and premenopausal nulliparous women: a multicentre randomised placebo controlled trial

Kesrouani

2018

BJOG

View full text Add to dashboard Cite

Misoprostol for cervical priming prior to hysteroscopy in postmenopausal and premenopausal nulliparous women: A multicentre randomised placebo controlled trial

Cited by 7 publications

References 0 publications

Electronic Continuous Pain Measurement vs Verbal Rating Scale in gynaecology: A prospective cohort study

Electronic Continuous Pain Measurement vs Verbal Rating Scale in gynaecology: A prospective cohort study

Authors' reply re: Misoprostol for cervical priming prior to hysteroscopy in postmenopausal and premenopausal nulliparous women; a multi‐centre randomised placebo controlled trial

Re: Misoprostol for cervical priming prior to hysteroscopy in postmenopausal and premenopausal nulliparous women: a multicentre randomised placebo controlled trial

Contact Info

Product

Resources

About